Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published ...

Verizon (NYSE:VZ) stock gained 2.2% after the telecoms giant reported fourth-quarter earnings and revenue that exceeded ...

If you are wondering whether Regeneron Pharmaceuticals is attractively priced right now, it helps to separate the headlines ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors ...

Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron ...

Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

Dupixent shows stable positive dynamics and becomes the main asset, while sales of Eylea are under pressure. Regeneron still has a strong pipeline, but the focus is shifting toward oncology. Valuation ...

Regeneron Pharma Inc. (REGN) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Order flow ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers. Over ...